Flores John Paul E, Diasio Robert B, Saif Muhammad Wasif
Division of Hematology/Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA (John Paul E. Flores, Muhammad Wasif Saif).
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN (Robert B. Diasio).
Ann Gastroenterol. 2017;30(1):54-61. doi: 10.20524/aog.2016.0074. Epub 2016 Jul 21.
Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient's individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more efficacious and cost effective. This is particularly relevant for pancreatic cancer, which currently portends a very poor prognosis. However, there is much to be done in this field, and more studies are needed to bring this concept to reality.
对大多数患者来说,胰腺癌仍然是一种致命疾病。个性化医疗时代已至:根据每位患者的个体癌症情况定制治疗方案。潜在地,治疗可以针对最有可能产生良好反应的个体,从而使其更有效且更具成本效益。这对于目前预后非常差的胰腺癌来说尤其重要。然而,在这个领域仍有许多工作要做,还需要更多研究将这一概念变为现实。